Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:04:53.397Z.
Calculation as of: 2026-10-06T18:04:53.397Z.
Quote observation: 2026-10-06T17:51:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e7a98ef6549bf85b46c4ba181efc1584300b0c5a2a31302d891700dc780dc00a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$10.56M
Price/FCF Ratio
N/A
TTM Avg
5.33
3Y Avg
5.33
5Y Avg
5.33
Market Cap
$10.51M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pluri Inc. (PLUR) | $10.59M | N/A | N/A | N/A | N/A |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.59M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.57M | N/A | N/A | N/A | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.56M | N/A | 5.33 | 5.33 | 5.33 |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.51M | N/A | N/A | N/A | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.37M | N/A | N/A | N/A | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.83M | N/A | N/A | N/A | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $10.30M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.94M | N/A | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.92M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
